• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.26% Nasdaq Up0.23%

    Alexion Pharmaceuticals, Inc. (ALXN)

    -NasdaqGS
    171.30 Down 1.20(0.70%) May 4, 4:00PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Alexion Pharmaceuticals, Inc.
    352 Knotter Drive
    Cheshire, CT 06410
    United States - Map
    Phone: 203-272-2596
    Fax: 203-271-8198
    Website: http://www.alexionpharm.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:2,273

    Business Summary 

    Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH and aHUS registry; Phase III clinical trials for the treatment of delayed kidney transplant graft function and myasthenia gravis; and Phase II clinical trials for the treatment of antibody mediated rejection in presensitized kidney transplant patients and neuromyelitis optica. In addition, it develops Asfotase alfa, a targeted enzyme replacement therapy that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1007, a novel humanized antibody in Phase II clinical trials for the treatment of anti-phospholipid syndrome and graft versus host disease; and cPMP (ALXN 1101) that is in Phase II trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development and commercialization of Moderna's messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Alexion Pharmaceuticals, Inc.

    Corporate Governance 
    Alexion Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Apr 1, 2015 is 3. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 1; Compensation: 6.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. Leonard Bell M.D., 57
    Co-Founder, Chairman of The Board and Consultant
    3.33M184.84M
    Mr. David L. Hallal , 49
    Chief Exec. Officer and Director
    1.50M5.09M
    Dr. Joseph A. Madri Ph.D., M.D., 68
    Co-Founder
    27.00KN/A
    Mr. Vikas Sinha M.B.A., C.A., CPA, 52
    Chief Financial Officer and Exec. VP
    1.43M23.10M
    Dr. Martin MacKay Ph.D., 58
    Global Head of R&D and Exec. VP
    1.36M2.35M
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders